The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1665
ISSUE1665
December 12, 2022
Opioids for Pain
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Opioids for Pain
December 12, 2022 (Issue: 1665)
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
- D Dowell et al. CDC clinical practice guideline for prescribing opioids for pain–United States, 2022. MMWR Recomm Rep 2022; 71:1.
- Nonopioid drugs for pain. Med Lett Drugs Ther 2022; 64:33.
- AK Chang et al. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized clinical trial. JAMA 2017; 318:1661.
- R Chou et al. Treatments for acute pain: a systematic review [Internet]. Comparative effectiveness review #240. Rockville (MD): Agency for Healthcare Research and Quality (US); December 2020. Report No.: 20(21)-EHC006. Available at: http://bit.ly/3UCZzvR. Accessed November 21, 2022.
- CJ Derry et al. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst Rev 2014 Dec; 2014 (12):CD009281.
- M Miller et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015; 175:608.
- RA Deyo et al. Association between initial opioid prescribing patterns and subsequent long-term use among opioid-naïve patients: a statewide retrospective cohort study. J Gen Intern Med 2017; 32:21.
- A Shah et al. Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep 2017; 66:265.
- Drugs for opioid use disorder. Med Lett Drugs Ther 2017; 59:89.
- R Chou et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways of Prevention Workshop. Ann Intern Med 2015; 162:276.
- DR Veiga et al. Effectiveness of opioids for chronic noncancer pain: a two-year multicenter, prospective cohort study with propensity score matching. J Pain 2019; 20:706.
- EE Krebs et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 2018; 319:872.
- Methylnaltrexone (Relistor) for opioid-induced constipation. Med Lett Drugs Ther 2008; 50:63.
- Naloxegol (Movantik) for opioid-induced constipation. Med Lett Drugs Ther 2015; 57:135.
- Naldemedine (Symproic) for opioid-induced constipation. Med Lett Drugs Ther 2017; 59:196.
- Lubiprostone (Amitiza) for opioid-induced constipation. Med Lett Drugs Ther 2013; 55:47.
- M Lee et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14:145.
- MJ Brennan. The effect of opioid therapy on endocrine function. Am J Med 2013; 126:S12.
- FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. March 22, 2016. Available at: http://bit.ly/3AiIT4w. Accessed November 21, 2022.
- FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. August 31, 2016. Available at: http://bit.ly/3UInBW8. Accessed November 21, 2022.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2021 October 20 (epub). Available at www.medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed November 21, 2022.
- Drug interactions: opioids and oral P2Y12 platelet inhibitors. Med Lett Drugs Ther 2019; 61:31.
- RHM Furtado et al. Morphine and cardiovascular outcomes among patients with non-ST-segment elevation acute coronary syndromes undergoing coronary angiography. J Am Coll Cardiol 2020; 75:289.
- VE Whiteman et al. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014; 2014:906723.
- RE Azuine et al. Prenatal risk factors and perinatal and postnatal outcomes associated with maternal opioid exposure in an urban, low-income, multiethnic US population. JAMA Netw Open 2019; 2:e196405.
- Substance Abuse and Mental Health Services Administration. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: 2018. Available at: http://bit.ly/3OaIZkr. Accessed November 21, 2022.
- HHS. Naloxone: the opioid reversal drug that saves lives. Available at: https://bit.ly/3k68NiV. Accessed November 21, 2022.
- Nalmefene returns for reversal of opioid overdose. Med Lett Drugs Ther 2022; 64:141.
- FDA warns against use of codeine and tramadol in children and breastfeeding women. Med Lett Drugs Ther 2017; 59:86.
- In brief: Heat and transdermal fentanyl. Med Lett Drugs Ther 2009; 51:64.
- FDA Drug Safety Communication: FDA requiring color changes to Duragesic (fentanyl) pain patches to aid safety―emphasizing that accidental exposure to used patches can cause death. September 23, 2013. Available at: http://bitly/3GkUxzO. Accessed November 21, 2022.
- Extended-release hydrocodone (Zohydro ER) for pain. Med Lett Drugs Ther 2014; 56:45.
- Extended-release hydrocodone (Hysingla ER) for pain. Med Lett Drugs Ther 2015; 57:71.
- Extended-release hydromorphone (Exalgo) for pain. Med Lett Drugs Ther 2011; 53:62.
- H Binsfeld et al. A randomized study to demonstrate noninferiority of once-daily OROS hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 2010; 10:404.
- E Bruera et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22:185.
- M Faul et al. Methadone prescribing and overdose and the association with Medicaid preferred drug list policies — United States, 2007–2014. MMWR Morb Mortal Wkly Rep 2017; 66:320.
- MJ Krantz et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387.
- Oliceridine (Olinvyk) - a new opioid for severe pain. Med Lett Drugs Ther 2021; 63:37.
- Oral oxymorphone (Opana). Med Lett Drugs Ther 2007; 49:3.
- FDA. Oxymorphone (marketed as Opana ER) information. February 6, 2018. Available at: https://bit.ly/3Gv2UJa. Accessed: November 21, 2022.
- Abuse-deterrent opioid formulations. Med Lett Drugs Ther 2015; 57:119.
- Arymo ER – a new abuse-deterrent morphine formulation. Med Lett Drugs Ther 2017; 59:68.
- A new abuse-deterrent opioid – Xtampza ER. Med Lett Drugs Ther 2016; 58:77.
- Tapentadol (Nucynta) – a new analgesic. Med Lett Drugs Ther 2009; 51:61.
- M Afilalo and B Morlion. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 2013; 16:27.
- Tramadol/celecoxib (Seglentis) for pain. Med Lett Drugs Ther 2022; 64:58.
- RM Duehmke et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6:CD003726.
- JP Fournier et al. Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. JAMA Intern Med 2015; 175:186.
- Transdermal buprenorphine (Butrans) for chronic pain. Med Lett Drugs Ther 2011; 53:31.
- Buprenorphine buccal film (Belbuca) for chronic pain. Med Lett Drugs Ther 2016; 58:47.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Opioids for Pain
Article code: 1665a
Article code: 1665a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.